{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pioglitazone", "query": { "intervention": "Pioglitazone" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 257, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pioglitazone&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T17:57:45.764Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00143520", "title": "Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Rivoglitazone", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 441, "start_date": "2004-12", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2021-05-10", "last_synced_at": "2026-09-02T17:57:45.764Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 71 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Columbiana", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00143520" }, { "nct_id": "NCT02697617", "title": "Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polycystic Kidney Disease" ], "interventions": [ { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 18, "start_date": "2016-01-26", "completion_date": "2020-01", "has_results": true, "last_update_posted_date": "2021-01-15", "last_synced_at": "2026-09-02T17:57:45.764Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02697617" }, { "nct_id": "NCT03471117", "title": "Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Kidney Diseases" ], "interventions": [ { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "The University of Texas at Arlington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "35 Years to 70 Years" }, "enrollment_count": 5, "start_date": "2018-04-01", "completion_date": "2020-01-14", "has_results": true, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-09-02T17:57:45.764Z", "location_count": 2, "location_summary": "Arlington, Texas • Dallas, Texas", "locations": [ { "city": "Arlington", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03471117" }, { "nct_id": "NCT00806520", "title": "Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Type 2 Diabetes" ], "interventions": [], "intervention_types": [], "sponsor": "HealthPartners Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2008-04", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2015-12-02", "last_synced_at": "2026-09-02T17:57:45.764Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00806520" }, { "nct_id": "NCT00970424", "title": "Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type II" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Dutogliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 252, "start_date": "2009-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-09-21", "last_synced_at": "2026-09-02T17:57:45.764Z", "location_count": 89, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Litchfield, Arizona + 77 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Litchfield", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00970424" }, { "nct_id": "NCT02298192", "title": "A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec/liraglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2014-11-21", "completion_date": "2015-12-23", "has_results": true, "last_update_posted_date": "2017-05-23", "last_synced_at": "2026-09-02T17:57:45.764Z", "location_count": 40, "location_summary": "Hamilton, Alabama • Chandler, Arizona • Glendale, Arizona + 34 more", "locations": [ { "city": "Hamilton", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02298192" }, { "nct_id": "NCT00189163", "title": "Pioglitazone in Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 40, "start_date": "2005-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-12-16", "last_synced_at": "2026-09-02T17:57:45.764Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00189163" }, { "nct_id": "NCT00975286", "title": "24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Thiazolidinedione (TZD)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 446, "start_date": "2009-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-09-02T17:57:45.764Z", "location_count": 23, "location_summary": "Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Mountain Home", "state": "Arkansas" }, { "city": "Concord", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00975286" }, { "nct_id": "NCT01183013", "title": "30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Pioglitazone 15 mg", "type": "DRUG" }, { "name": "Pioglitazone 45 mg", "type": "DRUG" }, { "name": "Pioglitazone 30 mg", "type": "DRUG" }, { "name": "Linagliptin 5mg / Pioglitazone 45 mg FDC", "type": "DRUG" }, { "name": "Linagliptin 5mg / Pioglitazone 30 mg FDC", "type": "DRUG" }, { "name": "Linagliptin 5mg", "type": "DRUG" }, { "name": "Linagliptin 5mg / Pioglitazone 15 mg FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 936, "start_date": "2010-08", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-10-20", "last_synced_at": "2026-09-02T17:57:45.764Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183013" }, { "nct_id": "NCT01309854", "title": "Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis", "Healthy Volunteers", "Pharmacokinetics", "Pioglitazone", "Drug-drug Interaction", "Amount of Pioglitazone in Blood" ], "interventions": [ { "name": "fostamatinib", "type": "DRUG" }, { "name": "pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 15, "start_date": "2011-03", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2011-07-07", "last_synced_at": "2026-09-02T17:57:45.764Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01309854" } ] }